Altimmune Class Action Lawsuit Filed
Analysis based on 10 articles · First reported Aug 19, 2025 · Last updated Sep 08, 2025
The market is negatively impacted by the significant decline in Altimmune's stock price, which fell by 53.2% in a single day following the disappointing trial results. This event also highlights the risks associated with investing in biotechnology companies and the potential for legal action against companies that allegedly provide misleading information to investors.
Levi & Korsinsky has initiated a class action securities lawsuit against Altimmune, Inc. on behalf of investors who suffered losses between August 10, 2023, and June 25, 2025. The lawsuit alleges securities fraud, stemming from Altimmune's June 26, 2025, announcement of topline results from its IMPACT Phase 2b MASH trial of Pemvidutide. The analysis revealed a failure to achieve statistical significance in the fibrosis reduction primary endpoint, attributed to a higher-than-expected placebo response. This news led to a dramatic 53.2% decline in Altimmune's common stock price, falling from $7.71 to $3.61 per share in one day. Joseph E. Levi and Levi & Korsinsky of Levi & Korsinsky are leading the effort to recover losses for affected shareholders, with a deadline of October 6, 2025, for investors to request to be appointed as lead plaintiff.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard